ASCO 2025: Focus on HER2+ mBC

Rebecca Shatsky, MDHER2 Breast Cancer | June 10, 2025

Dr. Shatsky weighs DESTINY-Breast09 findings and highlights the need to balance efficacy with long-term quality of life.

Rupert Bartsch, MDHER2 Breast Cancer | June 6, 2025

HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD.

Maryam Lustberg, MD, MPHHER2 Breast Cancer | June 5, 2025

Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment.

Stephanie L. Graff, MDHER2 Breast Cancer | June 5, 2025

Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.

Yvette C. TerrieHER2 Breast Cancer | June 3, 2025

T-DXd plus pertuzumab significantly improves PFS vs THP in HER2+ mBC, per interim results from DESTINY-Breast09.

Yvette C. TerrieHER2 Breast Cancer | June 3, 2025

THP delivers similar pCR and better tolerability than TCbHP for HER2+ early breast cancer, per phase 3 neoCARHP trial.

Yvette C. TerrieHER2 Breast Cancer | May 31, 2025

T-DXd improves PFS and cORR over chemo in HER2-low/ultralow HR+ mBC, regardless of PI3K, ESR1, or BRCA1/2 mutations.

Yvette C. TerrieHER2 Breast Cancer | May 31, 2025

T-DXd rechallenge after grade 1 ILD showed high success and prolonged benefit, with low recurrence and no grade 5 events.

Lauren Dembeck, PhDHER2 Breast Cancer | May 31, 2025

Trastuzumab rezetecan shows strong intracranial activity in HER2+ breast cancer with brain metastases in REIN trial.